SLN241220C2500
- 0.00
- 0.000.00%
Silence Therapeutics Newsroom
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
Silence Therapeutics: Anticipated Zerlasiran Partnership and Favorable Pelacarsen CVOT Outlook Drive Buy Rating
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Express News | Silence Therapeutics PLC : Jefferies Cuts Target Price to $31 From $38
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics Analyst Ratings
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Top 3 Health Care Stocks You'll Regret Missing In Q4
Silence Therapeutics Showcases Promising Phase 2 Results
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose
European Equities Traded in the US as American Depositary Rise in Monday Trading
Risks Still Elevated At These Prices As Silence Therapeutics Plc (NASDAQ:SLN) Shares Dive 31%
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Promising RNAi Developments Boost Silence Therapeutics' Buy Rating
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
6-K: Report of foreign private issuer (related to financial reporting)
Silence Therapeutics Q3 EPS $(0.21) Down From $(0.09) YoY, Sales $1.25M Down From $3.54M YoY
Silence Therapeutics 3Q Rev GBP1.14M >SLN